Intraoperative parathyroid hormone assays

Authors:: Carmen C Solórzano, MD, FACS, FSSO; Denise M Carneiro-Pla, MD, FACS
Section Editor:: Sally E Carty, MD, FACS
Deputy Editor:: Wenliang Chen, MD, PhD

Literature review current through: Jan 2024.

This topic last updated: Sep 14, 2022.

INTRODUCTION — Surgical resection of abnormal parathyroid glands is the only curative treatment for primary hyperparathyroidism [1,2]. Abnormal parathyroid glands can be removed via bilateral neck exploration or focused parathyroidectomy.

The bilateral neck exploration approach relies on visual inspection of all parathyroid glands to ensure that all abnormal ones are removed [3,4]. The focused approach, however, does not require exposure of all glands. Thus, a focused parathyroidectomy requires nonvisual confirmation that all abnormal glands have been removed in order to prevent higher failure rates.

Intraoperative parathyroid hormone (PTH) monitoring leverages the short half-life of the PTH hormone (three to five minutes) to provide the necessary assurance that a focused parathyroidectomy has been adequately performed (ie, all hypersecreting glands have been removed) before concluding the surgery [5-8]. In addition, intraoperative PTH measurements accurately predict postoperative calcium levels [7,9-17].

The use of intraoperative PTH monitoring in patients with sporadic primary hyperparathyroidism will be reviewed here. Parathyroid surgery techniques, preoperative localization of parathyroid glands, and the medical management of hyperparathyroidism are discussed elsewhere. (See "Parathyroid exploration for primary hyperparathyroidism" and "Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism" and "Primary hyperparathyroidism: Management".)

INTRAOPERATIVE PTH ASSAY — Parathyroid hormone (PTH) assays measure circulating levels of PTH. Because the half-life of the parathyroid hormone is very short (three to five minutes), the PTH level becomes a reliable surrogate for in vivo parathyroid function. (See "Parathyroid hormone assays and their clinical use".)

Intraoperative PTH monitoring utilizes one of the rapid immunochemiluminescence assays, which allows for repeated measurements of PTH levels while the patient is in the operating room [18-20]. The assays can be completed with a turnaround time of 8 to 20 minutes [21]. The intraoperative PTH assay should be performed in or close to the operating room to avoid delay caused by sample transport. Because of the large number of samples required to apply the intraoperative monitoring protocols, the facility is required to have a PTH assay with a fast turnaround time (<15 minutes).

To perform intraoperative PTH monitoring during parathyroid surgery, blood samples are collected at predetermined time intervals by the anesthetist (via an established peripheral venous or arterial line) or the surgeon (via a needle puncture of the internal jugular vein, anterior jugular vein, or external jugular vein in the operative field). For each sample, 3 to 5 mL of whole blood is collected in an ethylenediamine tetraacetic acid (EDTA) tube. It is important to avoid hemolysis during blood collection by filling the EDTA tube completely and avoiding any shaking of the sample [22,23]. Blood samples are then sent for PTH measurement, the results of which are interpreted according to one of the intraoperative PTH monitoring protocols.

INTRAOPERATIVE PTH MONITORING PROTOCOLS — Intraoperative parathyroid hormone (PTH) monitoring protocols help guide the surgical decision-making process. When properly followed, an established intraoperative PTH monitoring protocol can provide assurance that all currently hyperfunctioning parathyroid tissue has been adequately excised before the surgical procedure is concluded.

At each facility, surgeons should consistently use a protocol that is practical, specific, and reproducible under their local conditions. The goal is to cure 97 to 99 percent of patients of primary hyperparathyroidism.

Commonly used protocols — The most commonly used intraoperative PTH monitoring protocols include the ">50 percent PTH drop criterion" protocol and the dual criterion protocol (table 1).

>50 percent PTH drop criterion — The >50 percent PTH drop criterion protocol typically uses four intraoperative PTH samples (pre-skin-incision, pre-gland-excision or 0 minute, 5 minutes post-gland-excision, 10 minutes post-gland-excision) to construct a curve (figure 1) [24-28]. Some centers omit the pre-gland-excision and/or the 5 minute sample due to concerns of cost or proximity to the laboratory. The timing of the second (pre-gland-excision or 0 minute) sample is most critical as a collection made too early (during parathyroid gland dissection) could potentially miss the peak PTH level and lead to false negative results. This sample should be collected as the last vessel to the parathyroid gland is ligated.

The >50 percent PTH drop criterion protocol sets a decrease in PTH values of >50 percent from the higher level of either the pre-skin-incision level or pre-gland-excision/0 minute level as the criterion to conclude surgery. As an example, if the PTH value at 10 minutes post-gland-excision decreases >50 percent from the pre-skin-incision level, the procedure can be stopped without further neck exploration or visualization of the remaining parathyroid glands.

If the PTH value does not decrease by >50 percent at 10 minutes after gland excision, the surgeon can repeat the PTH level at 20 minutes. In most patients, the >50 percent PTH drop criterion is met with this additional measurement [25,29]. If the criterion is still not met after 20 minutes, surgery is continued by examining the other glands. The same protocol for blood sampling is repeated for each additional gland removed or, if all glands appear abnormal, after all abnormal tissue has been removed.

In retrospective studies, the >50 percent PTH drop criterion predicted postoperative eucalcemia with an accuracy of 96 to 97 percent for at least six months [25,30,31].

Dual criteria protocol — Another widely used method for PTH monitoring, the dual criteria protocol, requires a minimum of two intraoperative samples (the pre-skin-incision sample and a post-gland-excision sample) (table 1) [9,32-35].

The first sample is obtained pre-incision after induction of anesthesia. The second blood sample is collected from the same site 10 minutes after excision of the abnormal parathyroid gland. If the second PTH value decreases >50 percent compared with the first sample and has returned to the normal range, the dual criteria are met and surgery is concluded [11,14,32,36]. If the second sample does not meet one or both criteria, a third sample is drawn 20 minutes after gland excision. If the third sample again fails to meet the dual criteria, further exploration is conducted until all abnormal glands are identified and removed.

Fulfillment of the dual criteria also predicts postoperative eucalcemia with an accuracy of 97 percent, according to a retrospective study of 1882 patients undergoing parathyroidectomy for primary hyperparathyroidism [9].

It is essential to mention that each intraoperative assay has its own normal range. For assays that do not publish a normal range, it is recommended that each institution determine their normal range locally.

Other protocols — Other protocols for intraoperative PTH monitoring have been proposed in which the timing of PTH sampling, the required magnitude of PTH decrease, or the required final PTH value is adjusted to make the protocol more or less stringent (table 1) [34,37,38].

More stringent protocol — The use of a more stringent protocol, such as requiring that the >50 percent decline in PTH occur at 5 minutes rather than 10 minutes postexcision, may decrease the number of operative failures but increase the incidence of unnecessary bilateral exploration [25]. In a series of 1882 patients who underwent parathyroidectomy using the >50 percent PTH drop criterion for primary hyperparathyroidism, 206 additional patients would have undergone unnecessary surgery if the criterion was required to be met at 5 rather than 10 minutes [9].

Another more stringent protocol requires that the intraoperative PTH fall by >50 percent and to a level below 40 pg/mL (which is below the upper limit of the normal range) [11,12,39]. This more stringent protocol, however, has not been evaluated prospectively but is associated with the lowest risk of persistence in retrospective studies [40].

In a retrospective review of 896 patients who underwent bilateral exploration parathyroidectomy, using a receiver operating characteristic (ROC) analysis, the authors found that a >72 percent decline in PTH intraoperatively was the best predictor of multiple gland disease [41].

Less stringent protocol — The use of a less stringent protocol minimizes unnecessary surgery but carries a higher risk of persistent hyperparathyroidism after surgery. As an example, some users of PTH monitoring accept any reduction as purportedly indicative of an adequate resection or omit altogether the use of PTH monitoring during unilateral surgery.

Technical and patient factors affecting all protocols — Technical and patient factors that can cause an insufficient decline in PTH levels include decreased renal clearance in patients with chronic renal insufficiency [42], baseline sample hemodilution or hemolysis (both decrease baseline PTH value) [23], a missed PTH peak (figure 1), and laboratory errors [21]. In addition, when the baseline PTH level is drawn from an internal jugular vein ipsilateral to an abnormal gland, it can take longer for the PTH level to decrease adequately after the abnormal gland is excised [43]. (See "Parathyroidectomy in end-stage kidney disease", section on 'Resect abnormal glands with intraoperative PTH monitoring'.)

These factors can unnecessarily prolong operative and anesthesia time by mandating additional PTH testing and may also direct unnecessary excision of parathyroid glands. When these issues are suspected, a downsloping postresection PTH curve can provide some assurance that the parathyroid surgery will predict cure and in fact is often used as a key finding in deciding when to conclude the surgery [44,45]. Patients with mild hypercalcemic or normocalcemic hyperparathyroidism may have a significantly slower intraoperative PTH decline compared with hypercalcemic patients [46,47].

Technical factors such as postexcision sample dilution or hemolysis (both decrease PTH value) can lead to a falsely adequate drop in PTH, which in turn can lead to missed multiglandular disease and operative failure.

Renal or hereditary hyperparathyroidism — It should be noted that most intraoperative PTH monitoring protocols are intended for patients undergoing surgery for sporadic primary hyperparathyroidism. Thus, when intraoperative PTH monitoring is used in patients with secondary or hereditary hyperparathyroidism, the usual protocols do not necessarily apply [48]. Nevertheless, retrospective studies have shown that intraoperative PTH monitoring in patients with chronic renal insufficiency and tertiary hyperparathyroidism is reliable [17,49,50]. (See "Parathyroid surgery for inherited syndromes", section on 'Intraoperative PTH monitoring' and "Parathyroidectomy in end-stage kidney disease", section on 'Resect abnormal glands with intraoperative PTH monitoring'.)

Patients with multiple endocrine neoplasia (MEN) syndrome, parathyroid carcinoma, and familial hyperparathyroidism have a higher risk of persistent or recurrent hyperparathyroidism after surgery, even when intraoperative PTH monitoring indicates that the surgery is adequate [5-8,23,27,51-53].

OTHER USES OF RAPID PTH ASSAYS — Although intraoperative parathyroid hormone (PTH) assays are primarily used in focused parathyroidectomies to determine the adequacy of surgery as detailed above, such assays can also be used to lateralize hyperfunctioning parathyroid glands preoperatively, identify missing parathyroid glands, or confirm the presence of parathyroid tissue.

Lateralization of hyperfunctioning parathyroid gland — Bilateral jugular venous PTH sampling can be performed preoperatively or intraoperatively to lateralize hyperfunctioning parathyroid gland(s) to one side of the neck. In patients with otherwise negative preoperative localization studies, a positive bilateral jugular venous PTH sampling (defined as ≥10 percent difference in PTH measurements) can convert a bilateral to a unilateral neck exploration.

Blood samples are taken from both internal jugular veins as distally as possible, under ultrasound guidance (figure 2). Bilateral jugular venous sampling led to a successful unilateral neck exploration in 70 to 80 percent of patients when used in conjunction with intraoperative PTH monitoring [54,55]. (See 'Intraoperative PTH monitoring protocols' above.)

Missing glands — Bilateral jugular venous sampling for PTH levels can also be performed at the time of neck exploration to localize a missing gland, especially during a difficult exploration. A unilateral elevation of PTH leads the surgeon to explore the ipsilateral side of the neck for a missing hyperfunctioning gland. Similar readings on both sides of the neck in the context of a missing gland may suggest the presence of hyperfunctioning parathyroid disease outside the neck (eg, in the mediastinum). (See "Parathyroid exploration for primary hyperparathyroidism", section on 'Missing gland'.)

Identifying parathyroid tissue — Pre- or intraoperative fine needle aspiration of parathyroid tissue for PTH measurement can differentiate parathyroid tissue from other tissues with a high specificity [56,57]. A 25 gauge needle attached to a syringe is used to collect the tissue sample. The aspirated content is diluted with 1 mL of saline solution and centrifuged, and the supernatant is used for PTH measurement with a rapid PTH assay [58]. This technique allows quick tissue identification of parathyroid tissue without frozen section, which can help distinguish an intrathyroidal parathyroid gland from a thyroid nodule or an enlarged lymph node. (See "Parathyroid exploration for primary hyperparathyroidism", section on 'First gland'.)

OUTCOMES — The outcomes of patients who undergo focused parathyroidectomy guided by intraoperative parathyroid hormone (PTH) monitoring support its use by the majority of endocrine surgeons.

Because imaging commonly misses multiple gland disease, most high-volume endocrine surgeons with complex practices use intraoperative PTH to guide not only focused parathyroidectomy but bilateral neck explorations as well [59,60].

●For patients with sporadic primary hyperparathyroidism, parathyroid exploration guided by intraoperative PTH monitoring is successful in >97 percent of cases, with less extensive surgical dissection, shorter operative times, and smaller incisions than bilateral neck exploration [5-8,32,36].

Although some specialists can perform a bilateral neck exploration with small incisions and as an outpatient procedure, it often leads to a more extensive dissection and excision of additional "enlarged" glands that are assumed to be hyperfunctioning [34,61-67]. However, gland size or weight does not always correlate with parathyroid function [68]. Compared with bilateral neck exploration, a focused parathyroidectomy guided by intraoperative PTH monitoring is not clearly associated with a higher recurrence rate [69,70]. However, the follow-up in these studies is limited [7,11,12,31,71-73].

●Focused operations using intraoperative PTH monitoring are often outpatient procedures. Compared with bilateral neck explorations that often require admission [59], focused operations can lead to a 50 percent decrease in hospital costs and patient charges, despite an increase in laboratory costs [66,74]. However, the costs are not different if bilateral neck exploration can be performed as an outpatient procedure as well [75].

●For patients with equivocal or negative preoperative localization studies [76] and those requiring reoperation [26,77,78], intraoperative PTH monitoring improves the operative success rate, allowing successful unilateral neck exploration in more than 80 percent of such patients.

●The incidence of multiglandular disease in patients with sporadic hyperparathyroidism ranges from 5 to 30 percent [79,80]. The use of the >50 percent PTH drop criterion results in multigland resections in 3 to 10 percent of patients with an operative success rate of 97 to 98 percent [30,38,69,81-84]. The rates of multiple gland resection are higher when the dual criteria are used or when a bilateral neck exploration is performed without substantial increase in success rates [18,31,33,63,75,85-87]. (See 'Commonly used protocols' above.)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Parathyroid surgery".)

SUMMARY AND RECOMMENDATIONS

●Goals – Intraoperative parathyroid hormone (PTH) monitoring allows a more focused, less invasive approach to parathyroidectomy and signals the need for more exploration when PTH drop criterion is not met. Monitoring changes in PTH levels during surgery for sporadic primary hyperparathyroidism provides a useful tool to indicate when all hyperfunctioning parathyroid tissue has been adequately excised and accurately predicts postoperative normal or low calcium levels. (See 'Introduction' above.)

●Rationale – Intraoperative PTH monitoring takes advantage of the short plasma half-life (three to five minutes) of PTH by using a rapid assay technique that allows measurements while the patient is still in the operating room. (See 'Intraoperative PTH assay' above.)

●Common protocols of intraoperative PTH monitoring – At each facility, surgeons should consistently use a protocol that is practical, specific, and reproducible under their local conditions, with the goal of curing 97 to 99 percent of patients of hyperparathyroidism. Two protocols are commonly used. (See 'Intraoperative PTH monitoring protocols' above.)

•The >50 percent PTH drop criterion typically uses four intraoperative PTH samples (pre-skin-incision, pre-gland-excision or 0 minute, 5 minutes post-gland-excision, 10 minutes post-gland-excision). Surgery is concluded when there is a decrease in PTH values of >50 percent from the higher level of either the pre-skin-incision level or pre-gland-excision level.

•The dual criteria require a minimum of two intraoperative samples (a pre-skin-incision level and another one at 10 minutes post-gland-excision). Surgery is concluded when the second PTH level decreases >50 percent compared with the first sample and has returned to the normal range.

The >50 percent PTH drop and dual criteria are intended for patients who have sporadic, primary hyperparathyroidism. They do not necessarily apply to patients with renal or hereditary hyperparathyroidism.

●Other uses of rapid PTH assays – Rapid PTH assays can also be used to lateralize hyperfunctioning parathyroid glands pre- and intraoperatively, identify missing parathyroid glands, or confirm the presence of parathyroid tissue. (See 'Other uses of rapid PTH assays' above.)

●Outcomes of intraoperative PTH monitoring – Intraoperative PTH monitoring allows some patients to undergo a focused parathyroidectomy with less time, less dissection, possibly lower cost and smaller incision, and equal success rate, compared with a bilateral neck exploration, but is also used for bilateral neck explorations by high-volume endocrine surgeons with complex practices. (See 'Outcomes' above.)

Fraker DL, Harsono H, Lewis R. Minimally invasive parathyroidectomy: benefits and requirements of localization, diagnosis, and intraoperative PTH monitoring. long-term results. World J Surg 2009; 33:2256.
Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg 2016; 151:959.
Norman J, Lopez J, Politz D. Abandoning unilateral parathyroidectomy: why we reversed our position after 15,000 parathyroid operations. J Am Coll Surg 2012; 214:260.
Chen H, Wang TS, Yen TW, et al. Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume. Ann Surg 2010; 252:691.
Irvin GL 3rd, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg 1991; 162:299.
Chapuis Y, Icard P, Fulla Y, et al. [Excision under local anesthesia of parathyroid adenomas. Criteria of selection and control of effectiveness. 35 cases]. Presse Med 1991; 20:2090.
Schneider DF, Mazeh H, Sippel RS, Chen H. Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery 2012; 152:1008.
Greene AB, Butler RS, McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg 2009; 209:332.
Richards ML, Thompson GB, Farley DR, Grant CS. An optimal algorithm for intraoperative parathyroid hormone monitoring. Arch Surg 2011; 146:280.
Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 2011; 253:585.
Wharry LI, Yip L, Armstrong MJ, et al. The final intraoperative parathyroid hormone level: how low should it go? World J Surg 2014; 38:558.
Rajaei MH, Bentz AM, Schneider DF, et al. Justified follow-up: a final intraoperative parathyroid hormone (ioPTH) Over 40 pg/mL is associated with an increased risk of persistence and recurrence in primary hyperparathyroidism. Ann Surg Oncol 2015; 22:454.
Lee S, Ryu H, Morris LF, et al. Operative failure in minimally invasive parathyroidectomy utilizing an intraoperative parathyroid hormone assay. Ann Surg Oncol 2014; 21:1878.
Wachtel H, Cerullo I, Bartlett EK, et al. What Can We Learn from Intraoperative Parathyroid Hormone Levels that Do Not Drop Appropriately? Ann Surg Oncol 2015; 22:1781.
Hughes DT, Miller BS, Park PB, et al. Factors in conversion from minimally invasive parathyroidectomy to bilateral parathyroid exploration for primary hyperparathyroidism. Surgery 2013; 154:1428.
Elfenbein DM, Weber S, Schneider DF, et al. CaPTHUS scoring model in primary hyperparathyroidism: can it eliminate the need for ioPTH testing? Ann Surg Oncol 2015; 22:1191.
Marcadis AR, Teo R, Ouyang W, et al. Successful parathyroidectomy guided by intraoperative parathyroid hormone monitoring for primary hyperparathyroidism is preserved in mild and moderate renal insufficiency. Surgery 2018; 163:633.
Carneiro DM, Irvin GL 3rd. Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration. Surgery 2000; 128:925.
Sokoll LJ, Drew H, Udelsman R. Intraoperative parathyroid hormone analysis: A study of 200 consecutive cases. Clin Chem 2000; 46:1662.
Delbridge LW, Dolan SJ, Hop TT, et al. Minimally invasive parathyroidectomy: 50 consecutive cases. Med J Aust 2000; 172:418.
Carneiro-Pla D. Contemporary and practical uses of intraoperative parathyroid hormone monitoring. Endocr Pract 2011; 17 Suppl 1:44.
Lippi G, Blanckaert N, Bonini P, et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008; 46:764.
Moalem J, Ruan DT, Farkas RL, et al. Prospective evaluation of the rate and impact of hemolysis on intraoperative parathyroid hormone (IOPTH) assay results. Ann Surg Oncol 2010; 17:2963.
Irvin GL 3rd, Prudhomme DL, Deriso GT, et al. A new approach to parathyroidectomy. Ann Surg 1994; 219:574.
Carneiro DM, Solorzano CC, Nader MC, et al. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 2003; 134:973.
Irvin GL 3rd, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg 2004; 28:1287.
Solórzano CC, Carneiro-Pla DM, Lew JI, et al. Intra-operative parathyroid hormone monitoring in patients with parathyroid cancer. Ann Surg Oncol 2007; 14:3216.
Irvin GL 3rd, Deriso GT 3rd. A new, practical intraoperative parathyroid hormone assay. Am J Surg 1994; 168:466.
Di Stasio E, Carrozza C, Pio Lombardi C, et al. Parathyroidectomy monitored by intra-operative PTH: the relevance of the 20 min end-point. Clin Biochem 2007; 40:595.
Johnson LR, Doherty G, Lairmore T, et al. Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy. Clin Chem 2001; 47:919.
Carneiro DM, Solorzano CC, Irvin GL 3rd. Recurrent disease after limited parathyroidectomy for sporadic primary hyperparathyroidism. J Am Coll Surg 2004; 199:849.
Carty SE, Worsey J, Virji MA, et al. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery 1997; 122:1107.
Burkey SH, Van Heerden JA, Farley DR, et al. Will directed parathyroidectomy utilizing the gamma probe or intraoperative parathyroid hormone assay replace bilateral cervical exploration as the preferred operation for primary hyperparathyroidism? World J Surg 2002; 26:914.
Chiu B, Sturgeon C, Angelos P. Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients. Arch Surg 2006; 141:483.
Yang GP, Levine S, Weigel RJ. A spike in parathyroid hormone during neck exploration may cause a false-negative intraoperative assay result. Arch Surg 2001; 136:945.
Carty SE, Roberts MM, Virji MA, et al. Elevated serum parathormone level after "concise parathyroidectomy" for primary sporadic hyperparathyroidism. Surgery 2002; 132:1086.
Irvin GL 3rd, Dembrow VD, Prudhomme DL. Clinical usefulness of an intraoperative "quick parathyroid hormone" assay. Surgery 1993; 114:1019.
Garner SC, Leight GS Jr. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery 1999; 126:1132.
Heller KS, Blumberg SN. Relation of final intraoperative parathyroid hormone level and outcome following parathyroidectomy. Arch Otolaryngol Head Neck Surg 2009; 135:1103.
Claflin J, Dhir A, Espinosa NM, et al. Intraoperative parathyroid hormone levels ≤40 pg/mL are associated with the lowest persistence rates after parathyroidectomy for primary hyperparathyroidism. Surgery 2019; 166:50.
Foley CS, Moore EC, Milas M, et al. RECEIVER OPERATING CHARACTERISTIC ANALYSIS OF INTRAOPERATIVE PARATHYROID HORMONE MONITORING TO DETERMINE OPTIMUM SENSITIVITY AND SPECIFICITY: ANALYSIS OF 896 CASES. Endocr Pract 2019; 25:1117.
Sohn JA, Oltmann SC, Schneider DF, et al. Is intraoperative parathyroid hormone testing in patients with renal insufficiency undergoing parathyroidectomy for primary hyperparathyroidism accurate? Am J Surg 2015; 209:483.
Beyer TD, Chen E, Ata A, et al. A prospective evaluation of the effect of sample collection site on intraoperative parathormone monitoring during parathyroidectomy. Surgery 2008; 144:504.
Wang TS, Pasieka JL, Carty SE. Techniques of parathyroid exploration at North American endocrine surgery fellowship programs: what the next generation is being taught. Am J Surg 2014; 207:527.
Carr AA, Yen TW, Wilson SD, et al. Using parathyroid hormone spikes during parathyroidectomy to guide intraoperative decision-making. J Surg Res 2017; 209:162.
Graves CE, McManus CM, Chabot JA, et al. Biochemical Profile Affects IOPTH Kinetics and Cure Rate in Primary Hyperparathyroidism. World J Surg 2020; 44:488.
Shawky MS, Sakr MF, Nabawi AS, et al. Influence of common clinical variables on intraoperative parathyroid hormone monitoring during surgery for primary hyperparathyroidism. J Endocrinol Invest 2020; 43:1205.
Ermer JP, Kelz RR, Fraker DL, Wachtel H. Intraoperative Parathyroid Hormone Monitoring in Parathyroidectomy for Tertiary Hyperparathyroidism. J Surg Res 2019; 244:77.
Sunkara B, Cohen MS, Miller BS, et al. Influence of concurrent chronic kidney disease on intraoperative parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism. Surgery 2018; 163:42.
Pitt SC, Panneerselvan R, Chen H, Sippel RS. Secondary and tertiary hyperparathyroidism: the utility of ioPTH monitoring. World J Surg 2010; 34:1343.
Nilubol N, Weisbrod AB, Weinstein LS, et al. Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy. World J Surg 2013; 37:1966.
Pieterman CR, van Hulsteijn LT, den Heijer M, et al. Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. Ann Surg 2012; 255:1171.
Carneiro DM, Irvin GL 3rd, Inabnet WB. Limited versus radical parathyroidectomy in familial isolated primary hyperparathyroidism. Surgery 2002; 132:1050.
Ito F, Sippel R, Lederman J, Chen H. The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg 2007; 245:959.
Carneiro-Pla D. Effectiveness of "office"-based, ultrasound-guided differential jugular venous sampling (DJVS) of parathormone in patients with primary hyperparathyroidism. Surgery 2009; 146:1014.
Doppman JL, Krudy AG, Marx SJ, et al. Aspiration of enlarged parathyroid glands for parathyroid hormone assay. Radiology 1983; 148:31.
Horányi J, Duffek L, Szlávik R, et al. Intraoperative determination of PTH concentrations in fine needle tissue aspirates to identify parathyroid tissue during parathyroidectomy. World J Surg 2010; 34:538.
Patel SG, Yip L, Wang TS, et al. Intraoperative parathyroid hormone aspiration: Implementation and technique. VideoEndocrinology 2016; 3.
Kiernan CM, Wang T, Perrier ND, et al. Bilateral Neck Exploration for Sporadic Primary Hyperparathyroidism: Use Patterns in 5,597 Patients Undergoing Parathyroidectomy in the Collaborative Endocrine Surgery Quality Improvement Program. J Am Coll Surg 2019; 228:652.
Ishii H, Stechman MJ, Watkinson JC, et al. A Review of Parathyroid Surgery for Primary Hyperparathyroidism from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS). World J Surg 2021; 45:782.
Miura D, Wada N, Arici C, et al. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg 2002; 26:926.
Perrier ND, Ituarte PH, Morita E, et al. Parathyroid surgery: separating promise from reality. J Clin Endocrinol Metab 2002; 87:1024.
Gordon LL, Snyder WH 3rd, Wians F Jr, et al. The validity of quick intraoperative parathyroid hormone assay: an evaluation in seventy-two patients based on gross morphologic criteria. Surgery 1999; 126:1030.
Weber CJ, Ritchie JC. Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration. Surgery 1999; 126:1139.
Riss P, Kaczirek K, Heinz G, et al. A "defined baseline" in PTH monitoring increases surgical success in patients with multiple gland disease. Surgery 2007; 142:398.
De Pasquale L, Gobatti D, Ravini ML, et al. Intra-operative testing for parathyroid hormone: the Central Laboratory option. J Endocrinol Invest 2008; 31:62.
Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg 2008; 248:420.
Liechty RD, Teter A, Suba EJ. The tiny parathyroid adenoma. Surgery 1986; 100:1048.
Genc H, Morita E, Perrier ND, et al. Differing histologic findings after bilateral and focused parathyroidectomy. J Am Coll Surg 2003; 196:535.
Miccoli P, Berti P, Materazzi G, et al. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: A prospective randomized trial. Surg Endosc 2008; 22:398.
Lew JI, Irvin GL 3rd. Focused parathyroidectomy guided by intra-operative parathormone monitoring does not miss multiglandular disease in patients with sporadic primary hyperparathyroidism: a 10-year outcome. Surgery 2009; 146:1021.
Norlén O, Wang KC, Tay YK, et al. No need to abandon focused parathyroidectomy: a multicenter study of long-term outcome after surgery for primary hyperparathyroidism. Ann Surg 2015; 261:991.
Ishii H, Mihai R, Watkinson JC, Kim DS. Systematic review of cure and recurrence rates following minimally invasive parathyroidectomy. BJS Open 2018; 2:364.
Chen H, Sokoll LJ, Udelsman R. Outpatient minimally invasive parathyroidectomy: a combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay. Surgery 1999; 126:1016.
Kiernan CM, Schlegel C, Isom C, et al. Ambulatory bilateral neck exploration for primary hyperparathyroidism: is it safe? Am J Surg 2016; 212:722.
Thier M, Nordenström E, Bergenfelz A, Westerdahl J. Surgery for patients with primary hyperparathyroidism and negative sestamibi scintigraphy--a feasibility study. Langenbecks Arch Surg 2009; 394:881.
Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999; 229:874.
Irvin GL 3rd, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg 2004; 239:704.
Gill MT, Dean M, Karr J, et al. Intraoperative parathyroid hormone assay: a necessary tool for multiglandular disease. Otolaryngol Head Neck Surg 2011; 144:691.
Lew JI, Solorzano CC, Montano RE, et al. Role of intraoperative parathormone monitoring during parathyroidectomy in patients with discordant localization studies. Surgery 2008; 144:299.
Miccoli P, Berti P, Materazzi G, et al. Results of video-assisted parathyroidectomy: single institution's six-year experience. World J Surg 2004; 28:1216.
Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol 2002; 146:783.
Inabnet WB 3rd, Dakin GF, Haber RS, et al. Targeted parathyroidectomy in the era of intraoperative parathormone monitoring. World J Surg 2002; 26:921.
Thanasoulis L, Bingener J, Sirinek K, Richards M. A successful application of the intraoperative parathyroid hormone assay in tertiary hyperparathyroidism. Am Surg 2007; 73:281.
Carneiro-Pla DM, Solorzano CC, Lew JI, Irvin GL 3rd. Long-term outcome of patients with intraoperative parathyroid level remaining above the normal range during parathyroidectomy. Surgery 2008; 144:989.
Tezelman S, Shen W, Shaver JK, et al. Double parathyroid adenomas. Clinical and biochemical characteristics before and after parathyroidectomy. Ann Surg 1993; 218:300.
Proye CA, Carnaille B, Bizard JP, et al. Multiglandular disease in seemingly sporadic primary hyperparathyroidism revisited: where are we in the early 1990s? A plea against unilateral parathyroid exploration. Surgery 1992; 112:1118.

Topic 15031 Version 17.0

خرید پکیج

Intraoperative parathyroid hormone assays

References